AGIOS PHARMACEUTICALS, INC. Payments for Repurchase of Equity
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- AGIOS PHARMACEUTICALS, INC. payments for repurchase of equity for fiscal 2023 was $0.00.
- AGIOS PHARMACEUTICALS, INC. payments for repurchase of equity for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- AGIOS PHARMACEUTICALS, INC. payments for repurchase of equity for fiscal 2021 was $802.49M.
- AGIOS PHARMACEUTICALS, INC. payments for repurchase of equity for fiscal 2020 was $0.00.
| Period end | Payments for Repurchase of Equity 3 month | Payments for Repurchase of Equity 12 month |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-15 | |
| 2022-12-31 | $0.00 10-K · filed 2024-02-15 | |
| 2021-12-31 | $802.49M 10-K · filed 2024-02-15 | |
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 | |
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |